Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 385

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 385
---
Registration Rights

Pursuant to a registration rights agreement entered
into on October 5, 2021, the holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion
of Working Capital Loans (and any Class A common stock issuable upon the exercise of the Private Placement Warrants and warrants
that may be issued upon conversion of Working Capital Loans and upon conversion of the Founder Shares) are entitled to registration rights,
requiring the Company to register such securities and any other securities of the Company acquired by them prior to the consummation
of a business combination for resale. The holders of these securities are entitled to make up to three demands, excluding short form
demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights
with respect to registration statements filed subsequent to the completion of a business combination. The registration rights agreement
does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the securities. The Company
will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The Company granted the underwriter a 45-day option
from the date of the final prospectus relating to the IPO to purchase up to 2,325,000 additional Units to cover over-allotments, if any,
at the IPO price less the underwriting discounts and commissions. On October 8, 2021, the underwriter partially exercised its over-allotment
option and purchased 2,000,000 units at $10.00 per unit.

The underwriter was paid a cash underwriting discount
of $0.20 per unit, or $3,100,000 in the aggregate at the closing of the IPO, of which $465,000 was reimbursed to the Company to pay for
additional advisors. The underwriter agreed to defer any additional fees related to the exercise of the over-allotment option until the
Company completes a business combination. As such, $400,000 of additional underwriting fees related to the over-allotment have been deferred.
In addition, the underwriter is entitled to deferred underwriting commissions of $0.50 per unit, or $8,750,000 ($9,150,000 in the
aggregate when including the $400,000 noted above) from the closing of the IPO. The deferred fee will become payable to the underwriter
from the amounts held in the Trust Account solely in the event that the